News
-
According to Agomab, the US Patent and Trademark Office (USPTO) has granted a composition of matter patent (US Patent No. 12,577,230) covering the company’s AGMB-447 inhaled ALK5 (TGFβR1) inhibitor through 2041. Agomab is developing AGMB-447… Read more . . .
-
ARS Pharmaceuticals announced that the FDA has approved an sNDA to remove the age requirement for the 1 mg dose of neffy epinephrine nasal spray for the treatment of anaphylaxis. A 2 mg dose of… Read more . . .
-
According to United Therapeutics, the Phase 3 TETON-1 trial of nebulized Tyvaso treprostinil inhalation solution in patients with idiopathic pulmonary fibrosis met its primary endpoint, demonstrating a 130.1 mL change in absolute FVC from baseline to… Read more . . .
-
According to Tonix Pharmaceuticals, researchers at Erasmus University Medical Center have initiated a Phase 1 study of Tonix’s TNX-1900 intranasal potentiated oxytocin in healthy female volunteers as a proof of concept for the potential use… Read more . . .
-
In April 2025, Avalyn Pharma announced plans to advance its AP02 nintedanib inhalation solution into a Phase 2 trial in patients with idiopathic pulmonary fibrosis. Avalyn has now announced the initiation of the Phase 2… Read more . . .
-
Everest Medicines announced that it has acquired Chinese development, manufacturing, and commercialization rights to Cardamyst etripamil nasal spray from Corxel Pharmaceuticals Hong Kong (formerly Ji Xing Pharmaceuticals). Ji Xing acquired the Chinese rights to etripamil… Read more . . .
-
According to Insmed, the Phase 3b ENCORE study of once-daily Arikayce amikacin liposome inhalation suspension plus azithromycin and ethambutol in patients with newly diagnosed Mycobacterium avium complex (MAC) lung infection met its primary endpoint. The study demonstrated a… Read more . . .
-
CDMO Experic and particle engineering specialist Flurry Powders have announced a partnership to offer development services for inhaled and nasal drug formulations that require specialized particle engineering and manufacturing. The companies cite potential opportunities for dry… Read more . . .
-
Interna Therapeutics has announced that under an agreement with the University of Oxford researchers led by Oxford’s Helen McShane will conduct a Phase 2a study of the company’s intranasal molecular nano-motor (MNM)-siRNA drug against SARS-CoV-2.… Read more . . .
-
Nexalis Therapeutics, which recently changed its name from InhaleRx, has announced the initiation of a Phase 1 trial of its IRX-616a cannabidiol MDI, which the company is developing for the treatment of panic disorder. In… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK